Dr. Sankhala on Challenges Facing the Treatment of Angiosarcoma

Kumar Sankhala, MD
Published: Tuesday, Jul 18, 2017



Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses challenges facing the treatment of angiosarcoma.

Angiosarcoma is a challenging subtype of sarcoma as it is a very aggressive tumor, explains Sankhala. There are some chemotherapy drugs such as paclitaxel and doxorubicin that respond very well but recurs and progresses quickly.

According to Sankhala, the discovery of the TRC105 and pazopanib will hopefully achieve prolonged stabilization of the responses in these patients with angiosarcoma, states Sankhala.
 
SELECTED
LANGUAGE


Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses challenges facing the treatment of angiosarcoma.

Angiosarcoma is a challenging subtype of sarcoma as it is a very aggressive tumor, explains Sankhala. There are some chemotherapy drugs such as paclitaxel and doxorubicin that respond very well but recurs and progresses quickly.

According to Sankhala, the discovery of the TRC105 and pazopanib will hopefully achieve prolonged stabilization of the responses in these patients with angiosarcoma, states Sankhala.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x